Theaflavin attenuates atherosclerosis by targeting GSK-3β to suppress pyroptosis and Promote Autophagy in macrophages.

This experimental study investigated theaflavin (TF) as a potential treatment for atherosclerosis (AS), focusing on its regulation of macrophage pyroptosis and autophagy via GSK-3β.

Human aortic tissues from controls and subjects with AS, twelve male ApoE-/- mice, and ox-LDL-induced Ana-1 mouse macrophages, including Gsdmd/Caspase-1-overexpressing and Gsdmd-deficient cells, were studied.

After 6 weeks of high-fat feeding, mice received TF (10 mg/kg/day, intraperitoneally) or PBS for 6 weeks; macrophages were stimulated with ox-LDL (20 μg/mL) and treated with TF for 48 h.

Oil Red O staining, immunofluorescence, Western blotting, ELISA, CRISPR/Cas9, molecular docking, cellular thermal shift assay, and co-immunoprecipitation were performed. Data were expressed as mean ± SD and analyzed using unpaired two-tailed t-tests or ANOVA with Dunnett's test.

TF attenuated aortic plaque formation and reduced GSDMD-N, C-CASP1, NLRP3, and IL-1β. In vitro, TF suppressed lipid uptake in Gsdmd- or Caspase-1-overexpressing macrophages but showed no effect in Gsdmd-deficient cells. TF interacted with GSK-3β, reduced p-GSK-3β(Tyr216), promoted autophagy, and enhanced GSK-3β-cathepsin B interaction.

TF attenuates AS progression by suppressing pyroptosis-mediated foam cell formation and promoting autophagy through modulation of GSK-3β activity.
Cardiovascular diseases
Care/Management
Policy

Authors

Yang Yang, Liao Liao, Yang Yang, Xia Xia, Qin Qin, Tang Tang, Li Li, Bian Bian, Du Du, Yong Yong, Fan Fan, Xu Xu
View on Pubmed
Share
Facebook
X (Twitter)
Bluesky
Linkedin
Copy to clipboard